<DOC>
	<DOCNO>NCT02631551</DOCNO>
	<brief_summary>Study evaluate efficacy safety GSP 301 NS compare placebo NS individual monotherapies ( comparators ) well efficacy monotherapies ( comparators ) versus placebo NS 14 day study treatment</brief_summary>
	<brief_title>Efficacy Safety Fixed Dose Combination GSP 301 Nasal Spray ( NS ) Treatment Seasonal Allergic Rhinitis ( SAR )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>1 . Aged 12 year older inclusive either sex . 2 . Documented clinical history SAR ( least 2 year precede Screening Visit [ Visit 1 ] ) exacerbation ( clinical evidence active symptom ) spring allergy season ( tree/grass pollen ) 3 . A 12hour reflective TNSS ≥ 8 possible 12 congestion score ≥ 2 AM assessment Screening Visit ( Visit 1 ) . 1 . Pregnant lactating woman . 2 . Plans travel outside know pollen area investigative site &gt; 24 hour last 7 day run period . 3 . History anaphylaxis and/or severe local reaction ( ) skin test . 4 . History positive test HIV , Hepatitis B Hepatitis C infection . 5 . Documented evidence acute significant chronic sinusitis chronic purulent postnasal drip . 6 . Subjects active pulmonary disorder infection . 7 . Subjects posterior subcapsular cataract glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
</DOC>